"Cost Savings" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Reductions in all or any portion of the costs of providing goods or services. Savings may be incurred by the provider or the consumer.
| Descriptor ID |
D017046
|
| MeSH Number(s) |
N03.219.151.160.200
|
| Concept/Terms |
Cost Savings- Cost Savings
- Cost Saving
- Saving, Cost
- Savings, Cost
|
Below are MeSH descriptors whose meaning is more general than "Cost Savings".
Below are MeSH descriptors whose meaning is more specific than "Cost Savings".
This graph shows the total number of publications written about "Cost Savings" by people in this website by year, and whether "Cost Savings" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 2 | 2 |
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 2 | 2 |
| 2002 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 2 | 2 | 4 |
| 2005 | 0 | 2 | 2 |
| 2008 | 1 | 0 | 1 |
| 2009 | 0 | 2 | 2 |
| 2010 | 1 | 0 | 1 |
| 2011 | 0 | 3 | 3 |
| 2012 | 2 | 3 | 5 |
| 2013 | 0 | 2 | 2 |
| 2014 | 3 | 2 | 5 |
| 2015 | 1 | 1 | 2 |
| 2016 | 0 | 3 | 3 |
| 2017 | 2 | 5 | 7 |
| 2018 | 2 | 1 | 3 |
| 2019 | 2 | 1 | 3 |
| 2020 | 1 | 1 | 2 |
| 2021 | 0 | 3 | 3 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cost Savings" by people in Profiles.
-
Selective type & screen for elective colectomy based on a transfusion risk score may generate substantial cost savings. Surg Endosc. 2022 Dec; 36(12):8817-8824.
-
Transitioning ifosfamide chemotherapy regimens to the ambulatory setting: reviewing cost savings and safety profile. Support Care Cancer. 2022 Mar; 30(3):2755-2766.
-
Significant hospitalization cost savings to the payer with a pharmacist-led mobile health intervention to improve medication safety in kidney transplant recipients. Am J Transplant. 2021 10; 21(10):3428-3435.
-
Cost-impact analysis of baroreflex activation therapy in chronic heart failure patients in the United States. BMC Cardiovasc Disord. 2021 03 26; 21(1):155.
-
Registry-based trials: a potential model for cost savings? Cardiol Young. 2020 Jun; 30(6):807-817.
-
Permanent inferior vena cava filters offer greater expected patient utility at lower predicted cost. J Vasc Surg Venous Lymphat Disord. 2020 07; 8(4):583-592.e5.
-
Assessing the value of coronary artery computed tomography as the first-line anatomical test for stable patients with indications for invasive angiography due to suspected coronary artery disease. Initial cost analysis in the CAT-CAD randomized trial. J Cardiovasc Comput Tomogr. 2020 Jan - Feb; 14(1):75-79.
-
Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada. Oncologist. 2019 04; 24(4):537-548.
-
Use of economic predictions to make formulary decisions. Am J Health Syst Pharm. 2019 Feb 08; 76(Supplement_1):S15-S20.
-
Indianapolis Provider's Use Of Wraparound Services Associated With Reduced Hospitalizations And Emergency Department Visits. Health Aff (Millwood). 2018 10; 37(10):1555-1561.